Another point that probably doesn’t quite fit in there but came out of a workshop we had a year or so ago, trying to look at directions, is that it’s important to admit that our knowledge is limited, it could be wrong. For example, as in the aspirin trial, it may not work at all. If we should be in a situation where we don’t take advantage of that study to learn more about the disease it’s almost criminal not to add another 15% or 20% expense to the study to be certain that if it doesn’t work we can learn more about the disease.

Go to Part II of this lecture

Go to Comment Form